国货替代逻辑兑现！基金经理看好本土增长驱动

Core Viewpoint - The article discusses the strong rebound of domestic brands in sectors such as consumer goods, pharmaceuticals, and technology, driven by the logic of domestic brand substitution and independent performance growth, leading to increased market share and revenue opportunities for these brands [2][3]. Group 1: Domestic Brand Substitution Logic - Public funds have heavily invested in domestic brands, particularly in the cosmetics sector, benefiting from the domestic brand substitution logic, as foreign competitors like Estée Lauder face challenges in the Chinese market [3]. - The stock of Estée Lauder has seen a cumulative decline of over 25% in the last four trading days, while domestic brands like Mao Geping and Shangmei have shown strong resilience, with increases of 6.30% and 3.89% respectively [3]. - In the infant formula sector, domestic brand China Feihe has surged over 10% in the Hong Kong market, supported by significant investments from Ping An Fund and GF Fund [3]. Group 2: Independent Performance Growth - The article emphasizes the importance of independent performance, highlighting that many domestic brands achieve stable growth by relying on the vast domestic market, with companies like Bosideng generating approximately 94% of their revenue from China [6]. - The motorcycle sector has seen a surge in interest for domestic brand Chunfeng Power, with 70 public funds including it in their top ten holdings, reflecting confidence in the brand's growth potential [7]. - The article notes that many companies, including internet and consumer goods firms, have achieved consistent performance growth without international operations, indicating a strong domestic market drive [7]. Group 3: Market Opportunities and External Factors - The article points out that the strong manufacturing capabilities and demand in the domestic market provide public funds with opportunities to capitalize on undervalued stocks that have been unfairly punished by market sentiment [8]. - The pharmaceutical sector is expected to remain resilient against external factors, with domestic innovative drug companies benefiting from supportive policies and technological advancements [9][10]. - The article mentions that the introduction of zero tariffs on certain cancer and rare disease drugs in early 2024 may further mitigate external impacts on the pharmaceutical sector [10].